Jiangsu Nanfang Medical
Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal, medical proof fabrics, adhesive tapes and bandages, sports protection, first-aid kits, and care products in China and internationally. It offers medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical … Read more
Jiangsu Nanfang Medical (603880) - Total Liabilities
Latest total liabilities as of September 2025: CN¥733.89 Million CNY
Based on the latest financial reports, Jiangsu Nanfang Medical (603880) has total liabilities worth CN¥733.89 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Nanfang Medical - Total Liabilities Trend (2012–2024)
This chart illustrates how Jiangsu Nanfang Medical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Nanfang Medical Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nanfang Medical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kelly Partners Group Holdings Limited
OTCQX:KPGHF
|
USA | $132.48 Million |
|
West Red Lake Gold Mines Ltd.
OTCGREY:WRLGF
|
USA | $158.29 Million |
|
FAP Agri Tbk PT
JK:FAPA
|
Indonesia | Rp6.13 Trillion |
|
Hubtown Limited
NSE:HUBTOWN
|
India | ₹31.54 Billion |
|
China Fangda Group Co Ltd
SHE:200055
|
China | HK$6.98 Billion |
|
Humedix Co Ltd
KQ:200670
|
Korea | ₩23.40 Billion |
|
Modiv Inc
NYSE:MDV
|
USA | $294.77 Million |
|
Golden Flower Tbk PT
JK:POLU
|
Indonesia | Rp82.15 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Jiangsu Nanfang Medical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nanfang Medical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nanfang Medical (2012–2024)
The table below shows the annual total liabilities of Jiangsu Nanfang Medical from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥772.14 Million | -3.86% |
| 2023-12-31 | CN¥803.11 Million | -3.91% |
| 2022-12-31 | CN¥835.75 Million | +44.02% |
| 2021-12-31 | CN¥580.29 Million | +56.06% |
| 2020-12-31 | CN¥371.84 Million | +23.09% |
| 2019-12-31 | CN¥302.08 Million | +5.70% |
| 2018-12-31 | CN¥285.78 Million | +0.13% |
| 2017-12-31 | CN¥285.40 Million | +9.82% |
| 2016-12-31 | CN¥259.87 Million | +3.59% |
| 2015-12-31 | CN¥250.86 Million | +10.95% |
| 2014-12-31 | CN¥226.10 Million | +10.41% |
| 2013-12-31 | CN¥204.78 Million | -20.75% |
| 2012-12-31 | CN¥258.41 Million | -- |